PROTHENA CORPORATION PUBLIC LIMITED COMPANY

Prothena Corporation is a biopharmaceutical company dedicated to pioneering new medicines for neurodegenerative and rare peripheral amyloid diseases. By integrating cutting-edge insights into neurological dysfunction with a deep understanding of protein misfolding, the firm develops antibody-based therapeutics that aim to restore normal protein regulation and deliver clinically meaningful benefits to patients.

The company's scientific programme is built on decades of expertise in protein dysregulation, which has yielded foundational discoveries and a robust pipeline of investigational drugs. Prothena's approach focuses on targeting misfolded proteins-an emerging strategy that shows promise for treating conditions affecting millions of people and their families worldwide. Through rigorous research and strategic collaborations, the organisation is advancing a diverse portfolio of novel therapeutics designed to address unmet medical needs in both the central nervous system and peripheral amyloid disorders.